SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
By M. Hoffmann, Hannah Kleine-Weber, S. Schroeder, Nadine Krüger, T. Herrler, Sandra Erichsen, T. Schiergens, G. Herrler, N. Wu, Andreas Nitsche and 3 more. 2020
18,267 citations recorded by the source corpus.
Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
Subfields: Infectious Diseases
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, neutral): “Both SARS-CoV-2 S and SARS-CoV S bind to angiotensin-converting enzyme 2 (ACE2), which serves as entry receptor (Hoffmann et al., 2020; Letko et al., 2020; Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Zhou et al., 2020c).”
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus (2020, neutral): “Spike monomers are comprised of an N-terminal S 1 subunit that mediates receptor binding and a membrane-proximal S 2 subunit that mediates membrane fusion (Hoffmann et al., 2020a; Walls et al., 2020; Wrapp et al., 2020).”
- TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells (2020, background): “Recently, Hoffmann et al (2020) (20) showed that pretreatment of human Caco-2 colon cells and human airway cells with camostat mesylate markedly”
- SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract (2020, background): “The spike (S) glycoprotein mediates viral entry via binding to the human angiotensin-converting enzyme (ACE2) (Hoffmann et al., 2020; Walls et al., 2020; Yan et al., 2020), followed by proteolytic processing by transmembrane protease, serine 2 (TMPRSS2), furin, and perhaps other lung proteases,…”
- Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual (2020, background): “Like SARS-CoV, SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry receptor binding with nM affinity (Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020) (Hoffmann et al., 2020; Letko et al., 2020; Ou et al., 2020).”
- SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 (2020, background): “It has previously been reported that SARS-CoV-2 infects target cells by interacting with ACE2 and that a possible reason for its higher virulence compared to SARS-CoV-1 may owe to an increase in ACE2 binding affinity (Hoffmann et al., 2020).”
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. (2020, background): “quartile range) interval from symptom onset to hospital admission is 7 (3-9) days.”
- Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization (2021, background): “Processing of S by host cell proteases, typically TMPRSS2, TMPRSS4, or endosomal cathepsins, facilitates the S2-dependent fusion of viral and host-cell membranes (Hoffmann et al., 2020; Zang et al., 2020).”
- Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays (2020, background): “The transfected cells then produce Spike-pseudotyped lentiviral particles that can be used to infect permissive cells that express the SARS-CoV-2 receptor protein, ACE2 [28,29,41,42].”